Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Intra-Osseous Co-Transplant of UCB and hMSC
- Conditions
- Interventions
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT02181478
- Locations
- 🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 12
- Registration Number
- NCT02176733
- Locations
- 🇫🇷
Centre Hospitalier Universitaire, Angers, France
Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 200
- Registration Number
- NCT02144857
- Locations
- 🇬🇷
Attikon Hospital, Athens, Greece
Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Target Recruit Count
- 21
- Registration Number
- NCT02144025
- Locations
- 🇲🇽
Servicio de Hematologia Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo Leon, Mexico
Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Mashhad University of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT02114073
- Locations
- 🇮🇷
Khatam Eye Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of
hATG+CsA vs hATG+CsA+Eltrombopag for SAA
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2020-12-22
- Target Recruit Count
- 202
- Registration Number
- NCT02099747
- Locations
- 🇨🇭
University Hospital Bern, Bern, Switzerland
🇳🇱UMCG, Groningen, Netherlands
🇨🇭University Hospital Zürich, Zürich, Switzerland
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
- Conditions
- Interventions
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Edward Holland, MD
- Registration Number
- NCT02028312
- Locations
- 🇺🇸
Cincinnati Eye Institute, Edgewood, Kentucky, United States
Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02016625
- Locations
- 🇩🇪
1241.61.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany
OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.
- Conditions
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 252
- Registration Number
- NCT02005562
Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease
- Conditions
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 100
- Registration Number
- NCT02004067
- Locations
- 🇧🇷
Departamento de Oftalmologia da Escola Paulista de Medicina - UNIFESP, Sao Paulo, SP, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.